Publications
EVIDENCE → INFERENCE → CARE
Publications
Scholarship exploring skin cancer while advancing how medical evidence is generated, interpreted, and translated into care.
Selected Publications
Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain
In this Perspective on the Science piece, published in the Journal of Cutaneous Oncology, we provide a multidisciplinary summary and perspective on the CheckMate 358 trial in advanced Merkel cell carcinoma, exploring the role of dual checkpoint blockade, challenges of trial interpretation, real-world practice patterns, and evolving views on therapeutic intent and long-term outcomes.”
The Evolving Role of ctDNA in Merkel Cell Carcinoma: Challenges and Opportunities
This Perspective on the Science piece, published in the Journal of Cutaneous Oncology we discuss the evolving role of circulating tumor DNA (ctDNA) in the management of Merkel Cell Carcinoma, highlighting findings from a recent multicenter study and insights from a multi-institutional Journal Club. Key opportunities and challenges related to ctDNA’s use in surveillance and treatment decision-making are explored.
Comparing First-Line Immunotherapy in Advanced Melanoma: No Clear Winner?
In this Perspective on Science piece, published in the Journal of Cutaneous Oncology, we reflect on the indirect treatment comparison analysis between RELATIVITY-047 and CheckMate 067 trial data.
Should Ipilimumab Be the New “Standard” for Refractory MCC?
In this editorial, published in the Journal of Cutaneous Oncology, we discuss the role of ipilimumab in anti-PD-1 refractory Merkel cell carcinoma. This topic was presented at the Third International Symposium for MCC in Houston, Texas on May 4th 2024.
Tumor-Infiltrating Lymphocyte Therapy Receives FDA Approval
In this editorial, published in the Journal of Cutaneous Oncology, we reflect on the recent approval of the first cellular therapy for melanoma.
Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma
In this article, published in JAMA Otolaryngology-Head & Neck Surgery, we present a cohort study of patients treated with neoadjuvant cemiplimab or pembrolizumab for advanced cSCC
The Prognostic Value of the Merkel Cell Polyomavirus Serum Antibody Test: A Dual Institutional Observational Study
In this preprint, subsequently published in Cancer, we evaluate the prognostic value of the Merkel Cell Polyomavirus serum antibody test
Perspectives on Medical Aid in Dying: A Multifaceted Ethical Discussion
In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the complex ethical considerations surrounding Medical Aid in Dying, integrating insights from a recent multi-institutional journal club discussion.
Imaging Surveillance for Stage III Melanoma: Should We Be Stalkers or Casual Observers?
In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the role of surveillance imaging for patients with high-risk melanoma.
Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma: Ready for Prime Time?
In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma”.
Neoadjuvant Nivo/Rela for Resectable Melanoma
In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Ipi/Nivo for Advanced MCC
In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article “Combined Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy for Advanced Merkel cell carcinoma - A Randomised, Open Label, Phase 2 Trial”.
Neoadjuvant ICI for Resectable CSCC
In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
